GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback